The Chairman of the Cardiovascular Medicine at the Cleveland Clinic, in Cleveland Ohio has reported that a drug known as Rosiglitazone (Adavandia(TM) raises a patents’ chances of a heart attack and death by 43%. The drug also has the same risk by 64% when compared to other drugs such as placebos and other anti-diabetic therapies.

With 65% of diabetic deaths being caused by heart attacks, these findings are sending up the red flags. 

Cleveland Clinic was founded in 1921, and continues to be one of the top hospitals in the United States. Therefore their findings are respected around the world.

If you know someone with diabetes, or if you have type 2 diabetes check this site out on line. Make a copy of the article and give it to those people that do not have a computer. When they have an appointment with their health care provider they can question them about the article.

Rosiglitazone is one of the primary therapies used to lower blood sugar in patients with type 2 diabetes. "However, the objective of lowering blood sugar is the reduction of the complications of diabetes," Dr. Nissen explains. "The effect of anti-diabetic therapy on cardiovascular outcomes is of critical importance because cardiovascular disease represents the overwhelming source of diabetic mortality. Unfortunately, rosiglitazone appears to increase, rather than decrease, the most serious complication of diabetes, heart disease.

http://www.medicalnewstoday.com/articles/71646.php

Post from: Blisstree

Diabetes And The Heart